%PDF-1.4
%
23 0 obj
<>
endobj
19 0 obj
<>
endobj
84 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2003-02-05T19:19:40Z
2024-03-28T11:36:32-07:00
2024-03-28T11:36:32-07:00
QuarkXPress. 4.11: AdobePS 8.6 (219)
application/pdf
Heather
2001-722.march
uuid:8e72281a-1dd2-11b2-0a00-5c09276d7200
uuid:8e72281d-1dd2-11b2-0a00-b80000000000
endstream
endobj
8 0 obj
<>
endobj
9 0 obj
<>
endobj
24 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
94 0 obj
[98 0 R]
endobj
95 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0793 Tw 9.7 0 0 10 54 548.1616 Tm
(no evidence that the underlying assumptions associated with)Tj
0.02499 Tw 0 -1.2 TD
(this analysis were violated.)Tj
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(DISCUSSION)Tj
/T1_0 1 Tf
0.0688 Tw 0 -1.2 TD
[(Few reports of oral )17.7 (TW)-301.1 (treatment in RA)-264 (exist in the English)]TJ
-0.0002 Tc 0 Tw T*
(literature)Tj
0.0004 Tc 6.3 0 0 6.5 89.0015 491.4616 Tm
(1-6)Tj
-0.00011 Tc 0.0946 Tw 9.7 0 0 10 97.4045 488.1616 Tm
[(. )54.8 (A)-289.7 (placebo controlled crossover study found sig-)]TJ
0.26421 Tw -4.4747 -1.2 Td
(nificant improvements in clinical and laboratory variables)Tj
0.02921 Tw T*
(after 12 weeks of treatment)Tj
0 Tc 0 Tw 6.3 0 0 6.5 161.233 467.4616 Tm
(4)Tj
-0.00011 Tc 0.02921 Tw 9.7 0 0 10 164.3855 464.1616 Tm
[(. )54.8 (Another recent study evaluating)]TJ
0.04781 Tw -11.3799 -1.2 Td
[(oral )17.7 (TW)-280.1 (reported significant dif)17.7 (ferences in )54.8 (ACR-20 response)]TJ
0.04649 Tw T*
(rates of 80%, 40%, and 0% after 20 weeks of high dose, low)Tj
0.16479 Tw T*
(dose, and placebo treatment, respectively)Tj
0 Tc 0 Tw 6.3 0 0 6.5 220.3668 431.4616 Tm
(6)Tj
-0.00011 Tc 0.147 Tw 9.7 0 0 10 223.5193 428.1616 Tm
[(. T)69.9 (opical )-17.7 (applica-)]TJ
0.0462 Tw -17.4762 -1.2 Td
[(tion of )17.8 (TW)-278.5 (has not been investigated, other than in the origi-)]TJ
0.1667 Tw T*
(nal randomized double blind placebo controlled study con-)Tj
-0.03391 Tw T*
(ducted in Guangzhou, China)Tj
0 Tc 0 Tw 6.3 0 0 6.5 163.9951 395.4616 Tm
(7)Tj
-0.00011 Tc -0.034 Tw 9.7 0 0 10 167.1475 392.1616 Tm
[(. )17.7 (The original trial reported a sig-)]TJ
0.04491 Tw -11.6647 -1.2 Td
[(nificant improvement in symptoms in patients with RA)-240 (treat-)]TJ
0.0555 Tw T*
[(ed with topical )17.7 (TW)91.7 (. Our reanalysis of these data using logis-)]TJ
0.2065 Tw T*
(tic regression analysis with adjustment for baseline imbal-)Tj
0.03819 Tw T*
(ances confirms the original findings and suggests that topical)Tj
0.02499 Tw T*
[(TW)-257.3 (appears to be ef)17.7 (ficacious in RA.)]TJ
0.1859 Tw 1.2371 -1.2 Td
(There are several limitations to this reanalysis. Data on)Tj
0.01891 Tw -1.2371 -1.2 Td
(MTX, auranofin, and NSAID use were not available to deter-)Tj
0.084 Tw T*
(mine whether these variables were balanced at baseline, and)Tj
0.1297 Tw T*
(hence these could not be included in the logistic regression)Tj
0.1514 Tw T*
[(analysis. )17.7 (The )54.9 (ACR-20 outcome measure required modifica-)]TJ
0.0555 Tw T*
(tion to accommodate the data collected, although only minor)Tj
0.20621 Tw T*
[(criteria were modified. Finally)64.8 (, the )]TJ
/T1_2 1 Tf
0 Tw [-0.1 (post-hoc)]TJ
/T1_0 1 Tf
0.2063 Tw 19.054 0 Td
(nature of this)Tj
0.062 Tw -19.0541 -1.2 Td
(analysis can only serve the purpose of generating a hypothe-)Tj
0 Tw T*
(sis.)Tj
-0.01379 Tw 1.2371 -1.2 Td
(This reanalysis confirms the results of the original trial and)Tj
0.375 Tw -1.2371 -1.2 Td
[(supports the therapeutic ef)17.7 (ficacy of topical )17.7 (TW)-607.3 (in RA.)]TJ
0.05389 Tw 27.2165 51.3 Td
[(However)39.7 (, because this analysis was performed )]TJ
/T1_2 1 Tf
0 Tw 19.2467 0 Td
(post-hoc)Tj
/T1_0 1 Tf
0.05389 Tw [-0.2 (, fur-)]TJ
0.04111 Tw -19.2467 -1.2 Td
[(ther rigorous investigations are needed to evaluate the ef)17.7 (fica-)]TJ
0.02499 Tw T*
[(cy of topical )17.7 (TW)-257.3 (therapy in RA.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 655.1616 Tm
[(1.)-875.1 (Y)110.8 (u D. Clinical observation of 144 cases of rheumatoid arthritis)]TJ
1.675 -1.25 Td
[(treated with glycoside of radix )17.7 (T)35 (ripterygium wilfordii. J )17.7 (T)35 (radit Chin)]TJ
0 Tc 0 -1.25 TD
(Med 1983;3:125-9.)Tj
-1.675 -1.25 Td
[(2.)-875 (Guo J, )36.8 (Y)110.9 (uan S, )17.7 (W)80 (ang X, Xu S, Li D. )17.7 (T)35.1 (ripterygium wilfordii hook F)]TJ
-0.00011 Tc 1.675 -1.25 Td
(in rheumatoid arthritis and ankylosing spondylitis. Chin Med J)Tj
0 Tc 0 Tw T*
(1981;94:405-12.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Guo J, Gao Z, Zang )54.8 (A, Bai R. Radix )17.7 (T)35 (ripterygium wilfordii hook F)]TJ
1.675 -1.25 Td
(in rheumatoid arthritis, ankylosing spondylitis and juvenile)Tj
T*
(rheumatoid arthritis. Chin Med J 1986;99:317-20.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (T)69.9 (ao X, Sun )36.8 (Y)128.9 (,)-0.1 ( Dong )36.8 (Y)128.9 (, et al. )54.8 (A)-220.1 (prospective, controlled, double-)]TJ
1.675 -1.25 Td
[(blind, cross-over study of )17.7 (T)35 (ripterygium wilfordii Hook F in)]TJ
T*
(treatment of rheumatoid arthritis. Chin Med J 1989;102:327-32.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (T)69.9 (ao X, Cush JJ, Garret M, Lipsky PE. )54.8 (A)-220.1 (phase I study of ethyl)]TJ
1.675 -1.25 Td
[(acetate extract of the Chinese antirheumatic herb )17.7 (T)35 (ripterygium)]TJ
T*
(wilfordii Hook F in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:2160-7.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (T)69.9 (ao X, )36.8 (Y)99.8 (ounger J, Fan FZ, )17.7 (W)79.9 (ang B, Lipsky PE. Benefit of an)]TJ
1.675 -1.25 Td
[(extract of )17.7 (T)35 (ripterygium )17.7 (W)39.9 (ilfordii Hook F in patients with)]TJ
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 2002;46:1735-43.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Deng Z, Lin )36.8 (Y)128.9 (,)-0.1 ( Ou R, He )36.8 (Y)128.9 (,)-0.1 ( )17.7 (W)79.9 (a)-0.1 (ng Z. )54.8 (A)-220.1 (further study on compound)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(T)Tj
-0.00011 Tc 0.02499 Tw 0.5759 0 Td
(ripterygium wildfordii hook film in treating rheumatoid arthritis at)Tj
-0.5759 -1.25 Td
[(active stage. J Guangzhou Univ )17.7 (T)35 (radit Chin Med 1998;15:180-3.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Qin )17.7 (W)91.9 (,)-0.1 ( Liu C, )36.8 (Y)99.8 (ang S, et al. )17.7 (T)35 (ripterygium wilfordii hook F in)]TJ
1.675 -1.25 Td
(systemic lupus erythematosus. Report of 103 cases. Chin Med J)Tj
0 Tc 0 Tw T*
(1981;94:827-34.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Xu )17.7 (WY)128.8 (, Zheng JR, Lu XY)128.8 (. )17.7 (T)35 (ripterygium in dermatologic therapy)64.8 (.)]TJ
1.675 -1.25 Td
(Int J Dermatol 1985;24:152-7.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (T)69.9 (ao X, Lipsky PE. )17.7 (The Chinese anti-inflammatory and)]TJ
2.175 -1.25 Td
[(immunosuppressive herbal remedy )17.7 (T)35 (ripterygium wilfordii hook F)79.7 (.)]TJ
T*
[(Rheum Dis Clin North )54.8 (Am 2000;26:29-50.)]TJ
-0.0369 Tc 0 Tw -2.1381 -1.25 Td
[(11)-36.9 (.)]TJ
-0.00011 Tc 0.02499 Tw 2.0881 0 Td
[(Shu H, Liu P)110.7 (, Huang G. Ef)17.7 (fects of )17.7 (T)35 (ripterygium wilfordii on the)]TJ
0.05 -1.25 Td
[(menstruation of 50 patients suf)17.7 (fering from rheumatoid arthritis \321)]TJ
T*
[(with a summary of its therapeutic ef)17.7 (fects in 12 cases of)]TJ
T*
[(menorrhagia. J )17.7 (T)35 (radit Chin Med 1984;4:237-40.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Lipsky PE, )17.7 (T)69.9 (ao X. )54.8 (A)-220.1 (potential new treatment for rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis: )17.7 (Thunder God vine. Semin )54.8 (Arthritis Rheum 1997;)]TJ
0 Tc 0 Tw T*
(26:713-23.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Steinbrocker O, )17.7 (T)35 (raeger CH, Batterman RC. )17.7 (Therapeutic criteria in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis. JAMA)-220.2 (1949;140:659-62.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M. )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology preliminary definition of improvement in)Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:727-35.)]TJ
ET
0 0 0 0 scn
438 770 120 -25 re
f
BT
0 0 0 1 scn
/T1_3 1 Tf
0 Tw 20.37 0 0 21 461.9631 753.6089 Tm
(2001-722-3)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Ciber)36.8 (e, et al: T)54.8 (ripterygium wilfor)36.8 (dii in RA)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(467)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f
0.5 w
109.22 59.09 396.48 -10.84 re
S
BT
0 0 0 1 scn
/GS1 gs
/T1_2 1 Tf
8 0 0 8 54 714.5293 Tm
(T)Tj
-0.03709 Tw 0.4641 0 Td
(able 3. )Tj
/T1_0 1 Tf
-0.00011 Tc [0.3 (Adjusted odds ratio for modified )54.8 (ACR-20 response in the final mul-)]TJ
0.02499 Tw -0.4641 -1.25 Td
(tivariable logistic regression model.)Tj
0 Tc 0 Tw 0 -2.5 TD
(V)Tj
-0.00011 Tc 0.02499 Tw 0.6111 0 Td
[(ariable)-6468.8 (Odds Ratio \(95% CI\))-5449.9 (p)]TJ
0 Tc 0 Tw -0.6111 -2.5 Td
(T)Tj
-0.00011 Tc 0.02499 Tw 0.5759 0 Td
(reatment group)Tj
0 Tw 0.2491 -1.25 Td
[(Placebo)-9859.8 (1)]TJ
0 Tc -0.0178 -1.25 Td
(T)Tj
0.02499 Tw 0.5759 0 Td
[(ripterygium)-5150.9 (8.1 \(1.9\32035.4\))-6029.7 (0.005)]TJ
-0.00011 Tc 0 Tw -1.3831 -1.25 Td
(Age*)Tj
/C2_0 1 Tf
0 Tc 0.825 -1.25 Td
<002A>Tj
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 1.0988 0 Td
[(41 years)-8541.9 (1)]TJ
0 Tc -1.0988 -1.25 Td
[(< 41 years)-6206.4 (7.0 \(1.6\32030.9\))-6279.7 (0.01)]TJ
-0.00011 Tc -0.825 -1.25 Td
[(ESR per 10 unit dif)17.7 (ference)-705.1 (1.6 \(1.1\3202.2\))-6529.8 (0.02)]TJ
T*
(*The median of 41 years was used to dichotomize age.)Tj
ET
54 697 m
293.5 697 l
54.5 677.5 m
295 677.5 l
54 596.5 m
293.5 596.5 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
45 0 obj
<>
endobj
37 0 obj
<>
endobj
41 0 obj
<>
endobj
29 0 obj
<>
endobj
28 0 obj
<>
endobj
77 0 obj
<>
endobj
89 0 obj
<>
endobj
30 0 obj
<>
endobj
32 0 obj
<>
endobj
27 0 obj
<>stream
HTQN0+XR !CD"备=v(x<]akg9#;eſIŇ˼wm+=K1n@ap'ؼDn,B#?Tk UYm;@g:U{H,CE1uKq#\%}J%:A}Vǻ_ԮU\l;Eg2'\Gξ*DԬYQiFٴQTB u4gk!Pq1`vpx]<'ɟ` /
endstream
endobj
31 0 obj
<>stream
HT{PSg)yܺ6kx/VhkRuEPA塔 U^B@! 4OR " lV akwuյ3{3g9;P[B&
Ӳ"Yd6sorhDTNO;XX]>A(CA!l]7dlDoDAv^* BV"x$H79i~*ݻ`78C9$-mR^¹oz,{VOoG:x"7B.UR/әt`˷ c+(+8ɖUqEy8cl\+58Ss>hbW+ˍuڻuk6#R&yi\ti$V[|kol_Rt˂D7ߑllk@x8tېg'sw앨`}N{`?ŬscvaHrm-hakXi=jZ_Q3aPF"$)O65)A{ajGTc'{gf ɥg-u:\Q*դF.)L:
~JBF&/P岲H!R+VUZhvR|k5pMP+.5Ve?T~-YFcJ(P ;9Lc#p1rPa+-0UBWJ7oRxs!8>>g|[82Jж>+dId,U,(
?(Y/